Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration
Potential $1bn Deal Value
Executive Summary
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.